RS57520B1 - Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r - Google Patents
Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4rInfo
- Publication number
- RS57520B1 RS57520B1 RS20180802A RSP20180802A RS57520B1 RS 57520 B1 RS57520 B1 RS 57520B1 RS 20180802 A RS20180802 A RS 20180802A RS P20180802 A RSP20180802 A RS P20180802A RS 57520 B1 RS57520 B1 RS 57520B1
- Authority
- RS
- Serbia
- Prior art keywords
- antagonist
- administering
- methods
- atopic dermatitis
- treating atopic
- Prior art date
Links
- 206010012438 Dermatitis atopic Diseases 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 201000008937 atopic dermatitis Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
- G01N2800/202—Dermatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261697972P | 2012-09-07 | 2012-09-07 | |
US201261738715P | 2012-12-18 | 2012-12-18 | |
US201361748588P | 2013-01-03 | 2013-01-03 | |
US201361764624P | 2013-02-14 | 2013-02-14 | |
US201361768229P | 2013-02-22 | 2013-02-22 | |
US201361770091P | 2013-02-27 | 2013-02-27 | |
US201361782420P | 2013-03-14 | 2013-03-14 | |
US201361816191P | 2013-04-26 | 2013-04-26 | |
FR1356759 | 2013-07-10 | ||
PCT/US2013/057898 WO2014039461A1 (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
EP13765844.9A EP2892927B1 (en) | 2012-09-07 | 2013-09-04 | Methods for treating atopic dermatitis by administering an il-4r antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
RS57520B1 true RS57520B1 (sr) | 2018-10-31 |
Family
ID=50233497
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20180802A RS57520B1 (sr) | 2012-09-07 | 2013-09-04 | Postupci za lečenje atopijskog dermatitisa primenom antagonista il-4r |
Country Status (29)
Country | Link |
---|---|
US (3) | US20140072583A1 (sr) |
EP (4) | EP2892927B1 (sr) |
JP (3) | JP6353838B2 (sr) |
KR (3) | KR102385501B1 (sr) |
CN (3) | CN118286430A (sr) |
AR (1) | AR092475A1 (sr) |
AU (4) | AU2013312868B2 (sr) |
BR (1) | BR112015005048A8 (sr) |
CA (1) | CA2883936C (sr) |
CY (1) | CY1121906T1 (sr) |
DK (1) | DK2892927T3 (sr) |
ES (1) | ES2675779T3 (sr) |
HK (1) | HK1209132A1 (sr) |
HR (1) | HRP20181227T1 (sr) |
HU (1) | HUE039387T2 (sr) |
IL (1) | IL237328B (sr) |
LT (1) | LT2892927T (sr) |
MX (1) | MX363193B (sr) |
NZ (3) | NZ630178A (sr) |
PL (1) | PL2892927T3 (sr) |
PT (1) | PT3889181T (sr) |
RS (1) | RS57520B1 (sr) |
RU (2) | RU2666630C2 (sr) |
SG (2) | SG10201701798TA (sr) |
SI (1) | SI2892927T1 (sr) |
TR (1) | TR201808181T4 (sr) |
TW (3) | TWI690328B (sr) |
UY (1) | UY35013A (sr) |
WO (1) | WO2014039461A1 (sr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL283424B2 (en) | 2010-10-06 | 2023-09-01 | Regeneron Pharma | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) |
EP4324479A3 (en) | 2012-08-21 | 2024-04-24 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
SI2892927T1 (sl) * | 2012-09-07 | 2018-10-30 | Regeneron Pharmaceuticals,Inc | Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R |
TWI633891B (zh) | 2013-06-04 | 2018-09-01 | 再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
SI3010539T1 (sl) | 2013-06-21 | 2019-11-29 | Regeneron Pharma | Postopki za zdravljenje nazalne polipoze z administriranjem antagonista IL-4R |
TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
EP3973987B1 (en) | 2014-02-21 | 2024-01-10 | Sanofi Biotechnology | Combination comprising an il-4r antagonist, a corticosteroid and a long-acting beta2-adrenergic agonist for treating asthma |
JP2017521059A (ja) * | 2014-06-17 | 2017-08-03 | ザイクローブ セラピューティクス, インク.Xycrobe Therapeutics, Inc. | 機械的に位置合わせされた光学的要素及びその製造方法 |
TW201628647A (zh) * | 2014-06-27 | 2016-08-16 | 賽諾菲公司 | 抗-il4-il13雙特異性抗體 |
PT3110848T (pt) * | 2014-09-24 | 2024-03-05 | Regeneron Pharma | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r |
EP3218412A1 (en) | 2014-11-14 | 2017-09-20 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
WO2016156588A1 (en) | 2015-04-02 | 2016-10-06 | Intervet International B.V. | Antibodies to canine interleukin-4 receptor alpha |
RU2749512C2 (ru) | 2015-04-14 | 2021-06-11 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента |
EP4420733A2 (en) | 2016-02-19 | 2024-08-28 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4 antagonist |
CN113372446A (zh) | 2016-06-08 | 2021-09-10 | 苏州康乃德生物医药有限公司 | 用于结合白细胞介素4受体的抗体 |
CA3035202A1 (en) * | 2016-09-01 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
KR20230006049A (ko) | 2016-09-22 | 2023-01-10 | 리제너론 파아마슈티컬스, 인크. | Il-4r 저해제 투여에 의한 중증 아토피 피부염의 치료 방법 |
WO2018057776A1 (en) | 2016-09-22 | 2018-03-29 | Regeneron Pharmaceuticals, Inc. | Methods for treating severe atopic dermatitis by administering an il-4r inhibitor |
CA3031589A1 (en) | 2016-09-23 | 2018-03-29 | Genentech, Inc. | Uses of il-13 antagonists for treating atopic dermatitis |
TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
US11053309B2 (en) | 2017-08-04 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating active eosinophilic esophagitis |
US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
AU2018360999A1 (en) * | 2017-10-31 | 2020-05-14 | Oneness Biotech Co. Ltd. | Treating IgE-mediated allergic diseases |
CA3081751A1 (en) | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same |
WO2019150607A1 (ja) * | 2018-01-31 | 2019-08-08 | MediDoc Search株式会社 | 広告提示方法、及び、広告提示システム |
EP3793597A1 (en) | 2018-05-13 | 2021-03-24 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r inhibitor |
CN112823005B (zh) | 2018-08-10 | 2024-08-20 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
WO2020092015A1 (en) * | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
US11497718B2 (en) | 2018-11-13 | 2022-11-15 | Dermavant Sciences GmbH | Use of tapinarof for the treatment of atopic dermatitis |
CN111494625B (zh) * | 2018-12-25 | 2022-06-21 | 江苏荃信生物医药股份有限公司 | 用于治疗il-4和/或il-13介导的信号转导相关的疾病的药物组合物 |
SG11202109002XA (en) | 2019-03-21 | 2021-09-29 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
CN111592597B (zh) * | 2019-05-29 | 2022-04-26 | 山东博安生物技术股份有限公司 | 白介素4受体(il-4r)结合蛋白及其用途 |
IL289613B2 (en) | 2019-08-05 | 2023-09-01 | Regeneron Pharma | IL-4R antagonist in combination with a scit regimen to increase immunotherapeutic efficacy and tolerability to a grass-specific allergen |
CN114173816A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 |
US11748800B1 (en) * | 2019-09-11 | 2023-09-05 | Life Spectacular, Inc. | Generating skin care recommendations for a user based on skin product attributes and user location and demographic data |
CN111825766B (zh) * | 2019-10-31 | 2021-05-11 | 上海洛启生物医药技术有限公司 | 抗il-4r单域抗体及其应用 |
BR112022011098A2 (pt) | 2019-12-09 | 2022-09-20 | Sanofi Biotechnology | Métodos para tratamento de distúrbios relacionados a il-4/il-13 digitalmente identificados |
IL296214A (en) | 2020-03-27 | 2022-11-01 | Regeneron Pharma | Methods for treating atopic dermatitis by administering an antagonist to il-4r |
EP4019547A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for il-4r and il-31 |
EP4019090A1 (en) | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-4r |
KR20230123993A (ko) | 2020-12-23 | 2023-08-24 | 누맙 세러퓨틱스 아게 | Il-31에 결합하는 항체 가변 도메인 |
US11581084B2 (en) * | 2020-12-29 | 2023-02-14 | Kpn Innovations, Llc. | Systems and methods for generating an alimentary plan for managing skin disorders |
EP4294809A1 (en) * | 2021-02-18 | 2023-12-27 | Aclaris Therapeutics, Inc. | Topical formulations of a jak 1/3 inhibitor and methods of use thereof for treatment of atopic dermatitis and other skin conditions |
WO2023028468A1 (en) | 2021-08-23 | 2023-03-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
WO2023191665A1 (en) * | 2022-03-31 | 2023-10-05 | Milaboratory, Limited Liability Company | ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF |
WO2024076731A1 (en) * | 2022-10-06 | 2024-04-11 | Regranion, Llc | Methods and compositions for treating hidradenitis suppurativa |
US20240141051A1 (en) | 2022-11-01 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating hand and foot dermatitis by administering an il-4r antagonist |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3315427B2 (ja) * | 1992-03-05 | 2002-08-19 | 大日本除蟲菊株式会社 | 皮膚炎治療剤 |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
EP2990420B1 (en) | 2000-05-26 | 2016-12-21 | Immunex Corporation | Use of interleukin-4 receptor antibodies and compositions thereof |
EP1304115B1 (en) * | 2000-07-26 | 2007-09-12 | Hououdou Co. Ltd. | Antipruritic compositions and compositions promoting wound healing |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP5234445B2 (ja) * | 2004-10-05 | 2013-07-10 | 源一郎 杣 | 薬剤 |
EP2301969B1 (en) | 2005-05-06 | 2015-12-23 | ZymoGenetics, Inc. | IL-31 monoclonal antibodies and methods of use |
ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
US7608693B2 (en) * | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
IL283424B2 (en) | 2010-10-06 | 2023-09-01 | Regeneron Pharma | Stabilized formulations that include antibodies against the interleukin receptor (il-4r) |
RU2453303C1 (ru) * | 2010-12-23 | 2012-06-20 | Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") | Фармацевтическая композиция для лечения атопического дерматита |
SI2892927T1 (sl) | 2012-09-07 | 2018-10-30 | Regeneron Pharmaceuticals,Inc | Metode zdravljenja atopijskega dermatitisa z dajanjem antagonista Il-4R |
-
2013
- 2013-09-04 SI SI201331084T patent/SI2892927T1/sl unknown
- 2013-09-04 SG SG10201701798TA patent/SG10201701798TA/en unknown
- 2013-09-04 HU HUE13765844A patent/HUE039387T2/hu unknown
- 2013-09-04 EP EP13765844.9A patent/EP2892927B1/en not_active Revoked
- 2013-09-04 EP EP24163612.5A patent/EP4374919A3/en active Pending
- 2013-09-04 NZ NZ630178A patent/NZ630178A/en unknown
- 2013-09-04 PL PL13765844T patent/PL2892927T3/pl unknown
- 2013-09-04 CA CA2883936A patent/CA2883936C/en active Active
- 2013-09-04 AU AU2013312868A patent/AU2013312868B2/en active Active
- 2013-09-04 WO PCT/US2013/057898 patent/WO2014039461A1/en active Application Filing
- 2013-09-04 JP JP2015531149A patent/JP6353838B2/ja active Active
- 2013-09-04 LT LTEP13765844.9T patent/LT2892927T/lt unknown
- 2013-09-04 MX MX2015002873A patent/MX363193B/es unknown
- 2013-09-04 KR KR1020217023487A patent/KR102385501B1/ko active IP Right Grant
- 2013-09-04 RU RU2015108073A patent/RU2666630C2/ru active
- 2013-09-04 RU RU2018131237A patent/RU2698907C2/ru active
- 2013-09-04 RS RS20180802A patent/RS57520B1/sr unknown
- 2013-09-04 EP EP18161065.0A patent/EP3354663A1/en not_active Withdrawn
- 2013-09-04 CN CN202410387417.1A patent/CN118286430A/zh active Pending
- 2013-09-04 SG SG11201501011WA patent/SG11201501011WA/en unknown
- 2013-09-04 ES ES13765844.9T patent/ES2675779T3/es active Active
- 2013-09-04 KR KR1020227011429A patent/KR102576903B1/ko active IP Right Grant
- 2013-09-04 US US14/017,333 patent/US20140072583A1/en not_active Abandoned
- 2013-09-04 EP EP21167811.5A patent/EP3889181B1/en active Active
- 2013-09-04 TR TR2018/08181T patent/TR201808181T4/tr unknown
- 2013-09-04 KR KR1020157008872A patent/KR102122708B1/ko active IP Right Grant
- 2013-09-04 BR BR112015005048A patent/BR112015005048A8/pt not_active Application Discontinuation
- 2013-09-04 PT PT211678115T patent/PT3889181T/pt unknown
- 2013-09-04 DK DK13765844.9T patent/DK2892927T3/en active
- 2013-09-04 NZ NZ748451A patent/NZ748451A/en unknown
- 2013-09-04 CN CN202410387527.8A patent/CN118286417A/zh active Pending
- 2013-09-04 NZ NZ731864A patent/NZ731864A/en unknown
- 2013-09-04 CN CN201380046623.6A patent/CN104995212A/zh active Pending
- 2013-09-05 TW TW102131927A patent/TWI690328B/zh active
- 2013-09-05 TW TW111134046A patent/TWI814575B/zh active
- 2013-09-05 TW TW107106951A patent/TWI699212B/zh active
- 2013-09-06 UY UY0001035013A patent/UY35013A/es unknown
- 2013-09-06 AR ARP130103184A patent/AR092475A1/es unknown
-
2015
- 2015-02-19 IL IL237328A patent/IL237328B/en unknown
- 2015-09-29 HK HK15109558.8A patent/HK1209132A1/xx not_active IP Right Cessation
-
2017
- 2017-05-31 US US15/610,267 patent/US20170333557A1/en not_active Abandoned
-
2018
- 2018-06-08 JP JP2018109925A patent/JP6637113B2/ja active Active
- 2018-06-18 AU AU2018204346A patent/AU2018204346B2/en active Active
- 2018-07-27 CY CY20181100782T patent/CY1121906T1/el unknown
- 2018-07-31 HR HRP20181227TT patent/HRP20181227T1/hr unknown
-
2019
- 2019-12-10 AU AU2019279946A patent/AU2019279946B2/en active Active
-
2021
- 2021-09-23 AU AU2021236538A patent/AU2021236538B2/en active Active
-
2022
- 2022-09-23 US US17/951,987 patent/US20230058395A1/en active Pending
-
2023
- 2023-03-29 JP JP2023052545A patent/JP2023082091A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181227T1 (hr) | Metode za liječenje atopijskog dermatitisa primjenom antagonista il-4r | |
HRP20181963T1 (hr) | Postupci za liječenje ili sprječavanje astme primjenom antagonista il-4r | |
HK1222567A1 (zh) | 通過施用 拮抗劑治療鼻息肉症的方法 | |
ZA201906339B (en) | Methods for treating pruritus | |
ZA201407459B (en) | Method and apparatus for subscription sharing | |
EP2851378A4 (en) | PROCESS FOR PRODUCING OXYMETHYLENE COPOLYMER | |
IL278968B (en) | Methods for the treatment of atopic dermatitis through the administration of an IL-4R antagonist | |
HK1209040A1 (en) | Methods for treating vestibulotoxicity | |
IL271284A (en) | Methods for treating or preventing asthma by administering an antagonist to -il-r4 | |
EP2736517A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ATOPIC DERMATITIS | |
HUE046410T2 (hu) | Eljárások orrpolipózis kezelésére IL-4R-antagonista beadásával |